Abstract
Buprenorphine lower-dose (5, 10 and 20 mg/h) transdermal patches, which are administered once every 7 days, are indicated in the management of chronic non-malignant pain. This review focuses on the labelling of this formulation (BuTrans®) in the EU. The analgesic efficacy of transdermal buprenorphine in patients with osteoarthritis of the hip and/or knee has been demonstrated to be equivalent to sublingual buprenorphine, noninferior to prolonged-release tramadol and generally superior to a matching transdermal placebo patch. When used together with regularly scheduled oral paracetamol (acetaminophen), transdermal buprenorphine was noninferior to codeine plus paracetamol. Transdermal buprenorphine has also shown analgesic efficacy in patients with chronic non-malignant pain of various causes.
Similar content being viewed by others
References
Kumar N. WHO normative guidelines on pain management: report of a delphi study to determine the need for guidelines and to identify the number and topics of guidelines that should be developed by WHO. Geneva: World Health Organization, 2007 Jun
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009 Feb; 10(2): 113–30
Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6(2): 107–12
Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8(4): 287–313
Scoping document for WHO treatment guidelines on chronic non-malignant pain in adults. Geneva: World Health Organization, 2008 Oct
BuTrans 5, 10 and 20ug/h transdermal patch: EU summary of product characteristics. Cambridge, UK: Napp Pharmaceuticals Limied, 2010 Mar 11
Plosker GL. Buprenorphine 5, 10 and 20mg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs 2011; 71(18): 2491–509
Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scand J Pain 2010; 1(3): 122–41
James IG, O’Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manage 2010 Aug; 40(2): 266–78
Karlsson M, Berggren AC. Efficacy and safety of lowdose transdermal buprenorphine patches (5, 10, and 20microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallelgroup noninferiority study. Clin Ther 2009 Mar; 31(3): 503–13
Munera C, Drehobl M, Sessler NE, et al. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. J Opioid Manag 2010; 6(3): 193–202
Conaghan PG, O’Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeineparacetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage 2011; 19: 930–8
Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 2010 May; 32(5): 844–60
Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag 2010; 15(3): 169–78
Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenanceof-analgesia study. Clin Ther 2007 Oct; 29(10): 2179–93
American College of Rheumatology. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [online]. Available from URL: http://www.rheumatology.org/practice/clinical/clinicianresearchers/outcomes-instrumentation/WOMAC.asp [Accessed 2011 Dec 22]
Schutter U, Ritzdorf I, Heckes B. 7-day buprenorphine patch-an option when therapy with tramadol or tilidine/ naloxone is inadequate: results of a non-intervention study [in German]. MMW-Fortschr Med 2010; 152(II): 62–9
Böhme K, Heckes B, Thomitzek K. Seven-day buprenorphine transdermal patch in multimorbid patients on longterm ibuprofen or diclofenac [in German]. MMW-Fortschr Med 2010; 152(IV): 125–32
Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006 May; 96(5): 627–32
Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009 Mar; 13(3): 219–30
Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006; 20 Suppl. 1: S3–8
Butrans (buprenorphine) transdermal system for transdermal administration: US prescribing information. Stamford (CT): Purdue Pharma L.P., 2010 Jun
Acknowledgements and Disclosures
This article was adapted from Drugs 2011; 71 (18): 2491-509,[7] and was reviewed by: R. Day, Therapeutics Centre, St Vincent’s Hospital, Sydney, NSW, Australia; J.J. Hernández, Pain Medicine and Palliative Care, Rosario University, Bogata, Colombia.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from the comments received were made by the authors on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Plosker, G.L., Lyseng-Williamson, K.A. Buprenorphine 5,10 and 20 μg/h Transdermal Patch: A Guide to Its Use in Chronic Non-Malignant Pain. CNS Drugs 26, 367–373 (2012). https://doi.org/10.2165/11208360-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11208360-000000000-00000